<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04907487</url>
  </required_header>
  <id_info>
    <org_study_id>JSY_2021_13</org_study_id>
    <nct_id>NCT04907487</nct_id>
  </id_info>
  <brief_title>Évaluation de l'Impact du Compressed Sensing Sur le Signal QSM</brief_title>
  <acronym>CS-QSM</acronym>
  <official_title>Évaluation de l'Impact du Compressed Sensing Sur le Signal QSM</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients who have agreed to participate in the study will complete the MRI protocol as part&#xD;
      of routine care, to which a maximum of four additional 25-minute sequences will be added.&#xD;
&#xD;
      MRI of routine care includes at least the following sequences:&#xD;
&#xD;
        -  3D T1 TFE (2 minutes)&#xD;
&#xD;
        -  T2 TSE (2 minutes)&#xD;
&#xD;
        -  3D FLAIR (3 minutes)&#xD;
&#xD;
      The sequences added by the research lasting 25 minutes are:&#xD;
&#xD;
        -  SWI QSM 1.0iso 8 echoes (10 minutes)&#xD;
&#xD;
        -  SWI QSM 1.0iso 8 echoes CS 6 (7 minutes)&#xD;
&#xD;
        -  SWI QSM 1.0iso 8 echoes CS 9 (5 minutes)&#xD;
&#xD;
        -  SWI QSM 1.0iso 8 echoes CS 12 (3 minutes)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who have agreed to participate in the study will complete the MRI protocol as part&#xD;
      of routine care, to which a maximum of four additional 25-minute sequences will be added.&#xD;
&#xD;
      MRI of routine care includes at least the following sequences:&#xD;
&#xD;
        -  3D T1 TFE (2 minutes)&#xD;
&#xD;
        -  T2 TSE (2 minutes)&#xD;
&#xD;
        -  3D FLAIR (3 minutes)&#xD;
&#xD;
      The sequences added by the research lasting 25 minutes are:&#xD;
&#xD;
        -  SWI QSM 1.0iso 8 echoes (10 minutes)&#xD;
&#xD;
        -  SWI QSM 1.0iso 8 echoes CS 6 (7 minutes)&#xD;
&#xD;
        -  SWI QSM 1.0iso 8 echoes CS 9 (5 minutes)&#xD;
&#xD;
        -  SWI QSM 1.0iso 8 echoes CS 12 (3 minutes)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>concordance of QSM signal with and without compressed-sensing in white matter</measure>
    <time_frame>1 DAY</time_frame>
    <description>concordance of QSM signal with and without compressed-sensing in white matter</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>MRI</condition>
  <arm_group>
    <arm_group_label>SEP</arm_group_label>
    <description>With Multiple Sclerosis as defined by McDonald's revised clinical or radiological spatial and temporal dissemination criteria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NO SEP</arm_group_label>
    <description>For patients with an indication to undergo a brain MRI and at low risk of inflammatory CNS disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>MRI of routine care includes at least the following sequences:&#xD;
3D T1 TFE (2 minutes)&#xD;
T2 TSE (2 minutes)&#xD;
3D FLAIR (3 minutes)&#xD;
The sequences added by the research lasting 25 minutes are:&#xD;
SWI QSM 1.0iso 8 echoes (10 minutes)&#xD;
SWI QSM 1.0iso 8 echoes CS 6 (7 minutes)&#xD;
SWI QSM 1.0iso 8 echoes CS 9 (5 minutes)&#xD;
SWI QSM 1.0iso 8 echoes CS 12 (3 minutes)</description>
    <arm_group_label>NO SEP</arm_group_label>
    <arm_group_label>SEP</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Two groups of patients will be included as part of this research protocol:&#xD;
&#xD;
          -  Group I: Patients with MS&#xD;
&#xD;
          -  Group II: Patients with an indication to undergo a brain MRI and at low risk of&#xD;
             inflammatory CNS pathology, age and gender matched with group I.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For patients with MS:&#xD;
&#xD;
          -  Patient over 18 years old&#xD;
&#xD;
          -  Presenting MS defined according to McDonald's revised criteria for spatial and&#xD;
             temporal clinical or radiological dissemination [16],&#xD;
&#xD;
          -  Should benefit as part of the care of an MRI examination with or without injection of&#xD;
             gadolinium&#xD;
&#xD;
          -  Express consent to participate in the study&#xD;
&#xD;
          -  Affiliate or beneficiary of a social security scheme&#xD;
&#xD;
        For patients with an indication to undergo a brain MRI and at low risk of inflammatory CNS&#xD;
        disease:&#xD;
&#xD;
          -  Patient over 18 years old&#xD;
&#xD;
          -  Should benefit as part of the care of an MRI examination with or without injection of&#xD;
             gadolinium&#xD;
&#xD;
          -  Express consent to participate in the study&#xD;
&#xD;
          -  Affiliate or beneficiary of a social security scheme&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  For patients with MS:&#xD;
&#xD;
          -  Patient benefiting from a legal protection measure&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
&#xD;
        For patients with an indication to undergo a brain MRI and at low risk of inflammatory CNS&#xD;
        disease:&#xD;
&#xD;
          -  Patient benefiting from a legal protection measure&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
&#xD;
          -  Patient with inflammatory and / or demyelinating pathology of the CNS&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>amélie YAVCHITZ</last_name>
    <phone>0148036454</phone>
    <email>ayavchitz@for.paris</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hhopital fondation adolphe de rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 25, 2021</study_first_submitted>
  <study_first_submitted_qc>May 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2021</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

